多转录组学分析确定NNAT为驱动各谱系垂体腺瘤侵袭表型的关键分子
本研究收集216份覆盖全部垂体腺瘤谱系的全转录组测序数据集及多个单细胞转录组数据集,结合Scissor算法与单细胞加权基因共表达网络分析,识别侵袭相关细胞亚群及其基因调控网络。分析发现NNAT-MAPK-p38轴促进垂体腺瘤细胞上皮-间质转化并驱动侵袭,并经体外与体内实验验证,提示NNAT可作为靶向治疗候选分子。
要点
- NNAT-MAPK-p38轴促进垂体腺瘤细胞上皮-间质转化并驱动侵袭。
- NNAT被确定为侵袭性垂体腺瘤靶向治疗的候选分子。
- 多转录组学与单细胞分析可识别侵袭相关细胞亚群及其调控网络。
核心结论
- NNAT-MAPK-p38轴促进垂体腺瘤细胞上皮-间质转化并驱动侵袭,NNAT是靶向治疗开发的候选分子。
研究设计与样本
- 研究收集216份代表全部垂体腺瘤谱系的全转录组测序数据集及多个单细胞转录组数据集。
- 采用Scissor算法识别侵袭相关细胞亚群,并以单细胞加权基因共表达网络分析描绘基因调控网络。
- 通过差异基因表达与通路富集分析探讨NNAT-MAPK对垂体腺瘤侵袭的作用。
- 发现经体外和体内实验验证,包括定量聚合酶链反应、CCK-8、集落形成、Transwell实验、蛋白质印迹、免疫组化和多重免疫荧光。
主要发现
- 多转录组学分析刻画了侵袭性垂体腺瘤的转录组图谱,并揭示肿瘤内活跃的RNA相互作用,尤其是mRNA与长链非编码RNA之间。
- 在单细胞水平确认了与侵袭性相关的特定细胞亚群。
- 在这些亚群表型相关基因调控网络中识别出NNAT-MAPK-p38轴,其促进垂体腺瘤细胞上皮-间质转化并驱动侵袭。
临床怎么用
- NNAT可作为侵袭性垂体腺瘤靶向治疗开发的候选分子,为常规治疗抵抗或术后复发患者提供潜在精准治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although histologically benign, invasive pituitary adenomas exhibit malignant-like biological behavior, characterized by local invasiveness and high proliferative activity. Clinical management remains challenging due to the absence of effective targeted therapies, difficulties with surgical resection, and high risks of postoperative residual disease and recurrence. Precise therapeutic targets are urgently needed. METHODS: To investigate molecular mechanisms underlying pituitary adenoma invasion and identify potential therapeutic targets, we collected 216 whole transcriptome sequencing datasets representing all pituitary adenoma lineages, along with several single-cell transcriptome datasets. The Scissor algorithm was utilized to identify invasion-associated cell subpopulations. Single-cell weighted gene co-expression network analysis delineated the underlying gene regulatory network. Differential gene expression and pathway enrichment analyses explored NNAT-MAPK contributions to pituitary adenoma invasion. Findings were validated through in vitro and in vivo experiments (quantitative polymerase chain reaction, CCK-8, colony formation, Transwell assays, western blotting, immunohistochemistry, and multiplex immunofluorescence). RESULTS: Multi-transcriptomics analysis comprehensively characterized the transcriptomic landscape of invasive pituitary adenomas and revealed active RNA interactions within these tumors, particularly between mRNAs and long non-coding RNAs. Specific cell subpopulations associated with invasiveness were confirmed at the single-cell level. Analysis of phenotype-associated gene regulatory networks within these subpopulations identified the NNAT-MAPK-p38 axis, which promotes epithelial-mesenchymal transition in pituitary adenoma cells and drives invasion. CONCLUSION: These findings enhance understanding of the mechanisms underlying pituitary adenoma invasiveness and identify NNAT as a candidate for targeted therapy development, offering potential precision treatment strategies for patients resistant to conventional therapies or experiencing recurrent disease after surgery. Pituitary adenoma is a common brain tumor whose invasive form can act like cancer, invading nearby tissues, resisting full removal, and often returning after surgery, with no targeted drugs available. We studied 216 patient samples to find out what drives this cancer-like behavior. We discovered that a molecule called NNAT activates a key pathway called NNAT–MAPK–p38, allowing tumor cells to spread. This finding identifies NNAT as a promising target for new precision drugs. Our research offers hope for better, more personalized treatments for patients with invasive pituitary adenoma, potentially improving outcomes and quality of life.
引用
- Liu M, Wang H, Guo J, et al. Multi-transcriptomics analysis identifies NNAT as a key molecule driving the invasive phenotype across all lineages of pituitary adenomas. Neuro Oncol. 2026. PMID: 42166756. doi:10.1093/neuonc/noag113
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。